Development of a rapid and high‐performance chemiluminescence immunoassay based on magnetic particles for protein S100B in human serum

Abstract

Protein S100B is a clinically useful non-invasive biomarker for brain cell damage. A rapid chemiluminescence immunoassay (CLIA) for S100B in human serum has been developed. Fluorescein isothiocyanate (FITC) and N-(aminobutyl)-N-(ethylisoluminol) (ABEI) are used to label two different monoclonal antibodies of anti-S100B. Protein S100B in serum combines with labeled antibodies and can form a sandwiched immunoreaction. A simplified separation procedure based on the use of magnetic particles (MPs) that were coated with anti-FITC antibody is performed to remove the unwanted materials. After adding the substrate solution, the relative light unit (RLU) of ABEI is measured and is found to be directly proportional to the concentration of S100B in serum. The relevant variables involved in the CLIA signals are optimized and the parameters of the proposed method are evaluated. The results demonstrate that the method is linear to 25 ng/mL S100B with a detection limit of 0.02 ng/mL. The coefficient of variation (CV) is < 5% and < 6% for intra- and interassay precision, respectively. The average recoveries are between 97 and 107%. The linearity-dilution effect produces a linear correlation coefficient of 0.9988. Compared with the commercial kit, the proposed method shows a correlation of 0.9897. The proposed method displays acceptable performance for quantification of S100B and is appropriate for use in clinical diagnosis.

A biosensor for S100B detection based on PSS-MA-GoldMag-LFIA in early clinical diagnosis of brain damage

“…The detection limit, coefficient of variation, and recovery rates indicated that our novel method exhibited high reproducibility with low deviation, and the recovery experiment confirmed the accuracy of this assay system. [27][28][29] These results indicated the stability of our detection system. We also provide a quantitative comparison of the novel approach and Elecsys® for measuring the serum concentration of S100B (216 samples).…”

Progress in chemical luminescence-based biosensors: A critical review

“…One possibility is to use magnetic nano-/micro-particles labeled with an antibody, so each analytical step is conducted without washing. Finally, the generated immunocomplex for a given analyte is removed from the solution, using a magnet, to be deposited in the measuring area for CL (Qin et al, 2012;Fu et al, 2012;Zhang et al, 2013) or ECL detection Gan et al, 2013;Zhou et al, 2013;Zhu et al, 2012;Liao et al, 2014). Gan et al (2013) described an ECL immunoassay for carbohydrate antigen 19-9 (CA 19-9) in serum.…”

Circulating Biomarkers in Malignant Melanoma

“…S100B is released by cell death and once in circulation it has a short halflife (30 min) [176]. Serum S100B quantification is usually performed by immunoassay-based techniques sometimes adapted to automated test platforms [177,178]. Most of these methods employ sandwich-type immunoassay configuration with two different antibodies directed to the beta subunit.…”